Trials / Not Yet Recruiting
Not Yet RecruitingNCT06389526
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
A Phase 1, Multicenter, Open-Label Study of CHS-1000 as a Single Agent and in Combination With Toripalimab-tpzi in Participants With Advanced or Metastatic Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Coherus Oncology, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this trial is to assess the tolerability and safety of CHS-1000 alone and in combination with toripalimab-tpzi in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CHS-1000 | Specified dose on specified days |
| BIOLOGICAL | Toripalimab | Specified dose on specified days |
Timeline
- Start date
- 2025-02-15
- Primary completion
- 2028-05-30
- Completion
- 2028-05-30
- First posted
- 2024-04-29
- Last updated
- 2024-09-19
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06389526. Inclusion in this directory is not an endorsement.